Capital Strategy: Revenue, Grants, Debt and Equity

The four kinds of money

Customer revenue is the cheapest capital there is. It dilutes no one, carries no interest and comes with the strongest possible evidence that the business works. Its cost is speed: a company funded only by its customers grows at the rate its customers pay.

Non-dilutive funding — grants, research contracts, prizes — costs no equity either, but it is narrow. It pays for specific work, usually research and development, and comes with reporting obligations and long lead times.

Debt costs interest and, for most young companies, a personal guarantee. It is the right money for a business with predictable cash flows or assets to borrow against, and the wrong money for one that may not have revenue for years, because a loan has to be repaid on a schedule whether or not the plan worked.

Equity costs ownership and some control. Angel and venture equity also carries an expectation, explained in Lesson 1.1: that the company is trying to become very large, quickly, and will eventually sell or list so the investors can be paid. That expectation is a feature when it matches the business and a trap when it does not. Many good businesses are poor venture investments, and raising venture money for them commits the founder to a growth path the business cannot follow.

Non-dilutive money is real money

For companies doing technical research, the US government runs the largest seed-stage program most founders never apply to. The Small Business Innovation Research and Small Business Technology Transfer programs — together branded America's Seed Fund — provide equity-free, non-dilutive funding to American small businesses through eleven participating federal agencies, coordinated by the Small Business Administration. The award ceilings are indexed: as of October 2026 an agency may make a Phase I award of up to 335,937 dollars and a Phase II award of up to 2,239,578 dollars without SBA approval, with larger awards requiring a waiver.

The trade is time and fit. Awards follow agency solicitations and review cycles, they fund defined research rather than general operations, and they come with obligations to report. For a deep-technology or life-science company, though, a Phase I and Phase II sequence can fund the work that turns a hypothesis into the data an equity investor will price — which means the equity round, when it comes, is raised against evidence rather than promise, at a better price.

Founders outside the US should look for the equivalents in their own jurisdiction; the logic is the same.

What debt actually asks of a small business

Debt for young companies is more available than founders assume and more personal than they expect. The SBA's flagship 7(a) program guarantees loans of up to 5 million dollars for working capital, equipment, real estate, refinancing and changes of ownership, to US for-profit businesses that meet SBA size standards, are creditworthy, and cannot obtain suitable credit elsewhere on reasonable terms.

The Federal Reserve's Small Business Credit Survey — the 2026 report covers the 2025 survey of firms with fewer than 500 employees — shows what borrowing looks like in practice. Eighty-six percent of employer firms use financing regularly, most commonly credit cards and loans. Of the firms that carry debt, 59 percent used a personal guarantee to secure it and 51 percent used business assets. Sixty percent of firms applied for some financing in the year before the survey; of the applicants, 42 percent received the full amount they sought, 36 percent received some or most, and 22 percent received none.

Two lessons follow. Debt is a realistic option for a business with revenue, and it preserves ownership. But for most small companies it is backed by the founder personally, which makes it the wrong instrument for an experiment that may fail — exactly the kind of company venture equity exists to fund.

Deciding which round you are raising

A workable way to decide is to ask three questions in order.

Could customers fund this? If the business can reach the next milestone on revenue, slower but owned, that is usually the better trade, and the equity raised later will be cheaper.

Is there work that non-dilutive money will pay for? If the next milestone is a research result, a grant can buy it without selling anything.

Is this a venture business? Be honest about the outcome distribution. If the realistic best case is a very good company rather than a fund-returning one, the right investors are angels who want that, revenue-based or bank lenders, or no outside capital at all — not a venture pipeline of firms that will each, correctly, say no.

Only when the answer to the third question is yes should the rest of this course's process — the ranked investor list, the staged pipeline, the term sheet — be pointed at venture funds. For placement agents the same three questions are the start of a client conversation: a mandate to raise equity for an issuer who should be borrowing is a mandate that will fail, and the desk's reputation goes with it.